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Abstract
Background: Vero cell culture-derived whole-virus H5N1 vaccines have been extensively tested in clinical trials and
consistently demonstrated to be safe and immunogenic; however, clinical efficacy is difficult to evaluate in the absence of
wide-spread human disease. A lethal mouse model has been utilized which allows investigation of the protective efficacy of
active vaccination or passive transfer of vaccine induced sera following lethal H5N1 challenge.
Methods: We used passive transfer of immune sera to investigate antibody-mediated protection elicited by a Vero cell-
derived, non-adjuvanted inactivated whole-virus H5N1 vaccine. Mice were injected intravenously with H5N1 vaccine-
induced rodent or human immune sera and subsequently challenged with a lethal dose of wild-type H5N1 virus.
Results: Passive transfer of H5N1 vaccine-induced mouse, guinea pig and human immune sera provided dose-dependent
protection of recipient mice against lethal challenge with wild-type H5N1 virus. Protective dose fifty values for serum H5N1
neutralizing antibody titers were calculated to be #1:11 for all immune sera, independently of source species.
Conclusions: These data underpin the confidence that the Vero cell culture-derived, whole-virus H5N1 vaccine will be
effective in a pandemic situation and support the use of neutralizing serum antibody titers as a correlate of protection for
H5N1 vaccines.
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Introduction
Highly pathogenic avian influenza (HPAI) viruses of subtype A/
H5N1 continue to circulate in poultry and wild birds throughout
Asia and Africa, causing sporadic human infections with a high
case fatality rate. To date, at least 534 laboratory-confirmed
human cases of H5N1 infections in 15 different countries have
been recorded, leading to 316 confirmed deaths [1]. If H5N1
viruses gain the ability to transmit efficiently between humans,
they have the potential to cause pandemics associated with
significant human morbidity and mortality.
As part of pandemic preparedness strategies, vaccines against
H5N1 and other HPAI viruses with pandemic potential are being
developed. Timely evaluation of candidate pandemic vaccines will
enable manufacturers and regulatory authorities to answer critical
questions regarding safety, immunogenicity and efficacy in
advance of large-scale immunization programs. A number of
H5N1 vaccines have been shown to be safe and immunogenic in
clinical trials and to protect rodents and ferrets from lethal
challenge with wild-type viruses (reviewed in [2]).
We have developed a Vero cell culture platform which is being
used for the large-scale production of both seasonal and pandemic
influenza vaccines [3,4]. Using the Vero platform, whole,
inactivated pandemic vaccines derived both from clade 1 H5N1
A/Vietnam/1203/2004 and clade 2.1 A/Indonesia/05/2005
wild-type H5N1 virus strains have been developed. These vaccines
have been shown to protect immunized mice from lethal challenge
with both homologous and heterologous wild-type H5N1 viruses
[5,6]. Several clinical trials have also been undertaken in which the
safety and potent immunogenicity of these vaccines has been
consistently demonstrated [7–9]. In a phase I/II trial, 76% of
subjects vaccinated with a non-adjuvanted 7.5 mg formulation
developed neutralizing antibody titers of 1:20 or more [8].
Compared with results from trials of non-adjuvanted split or
subunit vaccines in which doses of 30 to 90 mg HA were required
to induce adequate immune responses [10,11], the whole-virus
vaccine has significant dose-sparing potential, which may be
critical in a pandemic scenario [12].
Cell culture-derived influenza vaccines also have several other
potential advantages when compared to conventional egg-derived
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vaccines using embryonated chicken eggs are cumbersome,
especially for highly pathogenic viruses such as H5N1 which
require the generation of reassortant viruses. In contrast, Vero
cells can be grown in modern, large-scale bioreactors, upscaling of
vaccine production can be rapidly and consistently achieved, and
all infectious production steps can be conducted at biosafety level
3, allowing the production of vaccines from highly pathogenic
wild-type strains [7]. Moreover, the growth of influenza in eggs has
been associated with the selection of antigenic variants that may be
suboptimal for inducing protective antibodies to wild-type virus
circulating in humans [13–15], whereas growth exclusively in
mammalian-derived tissue culture was reported to be representa-
tive of the natural virus [16–18].
H5N1 infections are severely pathogenic in humans, but, since
such viruses have yet to achieve efficient inter-human transmis-
sion, disease is not widespread and it is therefore difficult to
determine clinical vaccine efficacy. Licensing guidelines for
pandemic influenza vaccines have been developed via bridging
to those established for seasonal influenza vaccines [2]. A better
understanding of the relationship between the human antibody
response elicited following immunization and protection from
disease will facilitate the development of effective H5N1
vaccines.
The role of antibodies in protection from disease can be
investigated using passive transfer of immune sera to animal
models followed by challenge with lethal doses of wild-type
virus. Passive transfer of vaccine-induced immune sera has been
used to study the mechanisms of antibody-mediated protection
against several highly pathogenic viruses including Nipah Virus
[19], Andes virus [20], Japanese Encephalitis virus [21],
Chikungunya virus [22] and Enterovirus 71 [23]. Passive
transfer has also been used to evaluate the protective efficacy of
human gammaglobulin or human monoclonal antibodies
against West Nile virus [24,25], Ebola virus [26,27], and
Dengue Fever virus [28]. In addition, passive transfer of
vaccine-induced immune sera between mice was used to
demonstrate the protective efficacy of a licensed pandemic
H1N1v vaccine [29], and several studies have revealed the
potential of monoclonal antibodies to protect animals from
lethal challenge with wild-type H5N1 virus [30–40]. To date,
however, investigations into the efficacy of H5N1 vaccine-
induced human immune sera to protect against lethal challenge
with wild-type virus have not been reported.
In the present study, we have evaluated the possibility of
utilizing passive transfer of H5N1 vaccine-induced immune sera
to bridge the data gap between vaccine immunogenicity
observed in humans and protection from disease observed in
animal models. Our results demonstrate that a Vero cell-
derived, inactivated whole-virus H5N1 vaccine elicits potent
humoral immune responses which following passive transfer
protect mice against lethal challenge with wild-type H5N1 virus,
and that protection correlates with serum neutralizing antibody
titers.
Materials and Methods
Ethics Statement
Human immune sera were obtained as part of a registered
clinical trial (ClinicalTrials.gov Identifier: NCT00462215) from
volunteers who agreed to and understood the clinical study
procedures and provided written consent to participation in the
study. All participants signed an informed consent form prior to
study entry permitting retained blood samples to be used for
immunological testing, provided that this is for the further
development of the vaccine. Clinical studies were conducted in
compliance with Good Clinical Practice guidelines and the
provisions of the Declaration of Helsinki. Ethics approval for
clinical studies was obtained from the ethics committees of all
institutions that participated in the study. Ethics approval was
obtained from the Ethics Committee of the Medical Department
of the Vienna General Hospital for clinical studies at the
University Clinic for Clinical Pharmacology, Vienna General
Hospital, Vienna, Austria, and the Centre for Travel Medicine,
Vienna, Austria. Ethics approval was obtained from the Ethics
Committee of Lower Austria for studies at the clinic of Dr.
Reinhard Lober, Wiener Neustadt, Niedero ¨sterreich, Austria.
Ethics approval was obtained from the Ethics Committee of the
city of Vienna for clinical studies at the Vaccination centre
Impfzentrum Nord, Vienna, Austria, and Sozialmedizinisches
Zentrum Su ¨d, Kaiser Franz Josef Hospital, Vienna, Austria. Ethics
approval was obtained from the the Ethics Committee of the
Medical Association of Rheinland-Pfalz for clinical studies at the
Hautklinik, Mainz University Clinic, Germany and the practice of
Dr. Schmitt and Dr. Regner, Mainz, Germany. Ethics approval
was obtained from the Ethics Committee of Berlin for clinical
studies at the Charite ´ Research Organisation GmbH, Berlin,
Germany.
All animal experiments were reviewed by the Baxter Institu-
tional Animal Care and Use Committee and approved by the
Austrian regulatory authorities. All animal experiments were
conducted in accordance with Austrian laws on animal experi-
mentation and guidelines set out by the Association for Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC) and the US Department of Health and Human
Services Office of Laboratory Animal Welfare (OLAW). Animals
were housed according to OLAW and AAALAC guidelines, in
housing facilities accredited by the AAALAC. The permit number
granted by the Lower Austrian provincial government for the
animal experiments performed during these studies is TVG-25/
043-2006.
Virus and vaccine
Wild-type A/H5N1/Vietnam/1203/04 virus (CDC#2004706280),
obtained from the Centers for Disease Control and Prevention
(CDC, Atlanta, USA) was propagated in serum-free Vero cell
cultures. The formalin and UV light double-inactivated whole-
virus vaccine was manufactured in an enhanced BSL-3 facility
and has been previously described [8].
Immune sera
Pooled sera were used for the majority of experiments since
mice and guinea pigs are too small to allow serum from individual
animals to be used to passively immunize groups of mice. Pools of
immune sera were obtained from CD1 mice or guinea pigs by
cardiac puncture 3 weeks following two immunizations, 3 weeks
apart with 3.75 mg of non-adjuvanted vaccine. Mouse and guinea
pig H5N1 antibody titers were determined by virus microneu-
tralization (MN) assay, hemagglutination inhibition (HI) assay and
ELISA. Pre-immune sera were collected for use as negative
controls.
Human immune sera were collected 3 weeks following two
immunizations, 3 weeks apart with 7.5 mg of vaccine, as part of a
phase III H5N1 vaccine safety and immunogenicity clinical trial
(ClinicalTrials.gov Identifier: NCT00462215). This trial recruited
583 participants, 561 of whom received at least one vaccination.
Blood was obtained by arm venipuncture. Serum was obtained by
letting blood rest at room temperature for 30 mins to 6 hours,
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tion for 10 mins at 1100 to 1300 x g at room temperature. Serum
was then frozen at #220uC. All individual human immune sera
collected as part of this trial were tested by MN assay, single radial
hemolysis (SRH) assay and HI assay, as requested by both
European and US regulatory agencies. Of these, antisera from 25
individuals were chosen for pooling, based on MN titers in
individual sera. Pools consisted of sera from between 2 and 12
individuals.
Passive immunization
CD1 mice were chosen for passive immunization experiments
since they are outbred, thus better reflecting the human genetic
situation. For single-injection experiments, groups of seven or ten
6–8 week old female CD1 mice were intravenously injected via the
tail vein with 200 ml of a range of dilutions of pooled, non-heat-
inactivated immune sera collected from mice, guinea pigs or
humans. Antisera were diluted in naı ¨ve serum derived from the
homologous species. Dilution factors were calculated to achieve
desired final concentrations of serum neutralizing antibodies based
on an estimated total blood volume of 1.5 ml [41]. For experi-
ments which used 3 successive immunizations, groups of five or ten
6–8 week old female CD1 mice were injected intraperitoneally
with 400 ml of undiluted human serum since, in our experience,
this route is more convenient and reproducible for larger volumes
of serum. Mice were bled 22 hours following passive immuniza-
tion and sera from individual mice in each group were pooled to
determine circulating H5N1 neutralizing antibody titers by MN
assay.
Virus challenge
Mice were challenged intranasally with 10
4 tissue culture
infectious dose fifty (TCID50), corresponding to 133 lethal dose
fifty (LD50) of H5N1 wild-type virus (A/Vietnam/1203/2004), 24
h post-passive transfer. Mice were monitored for a period of 14
days for disease signs and death as a result of H5N1 challenge.
Animals that survived 14 days post challenge were considered
protected.
CPE-based MN assay
H5N1 neutralizing antibody titers in pooled immune sera were
determined via a cytopathic effect (CPE)-based MN assay as
previously described [8]. Briefly, serum samples were heat
inactivated at 56uC for 30 mins, then serially diluted with cell
culture medium in two-fold steps. Dilutions were mixed 1:1 with
wild-type A/Vietnam/1203/2004 virus (100 TCID50 per well),
incubated for 1 h at RT and eight-fold replicates per dilution were
transferred to a microtiter plate with a Vero cell monolayer
(1610
4 cells per well). After 5–7 days incubation at 37uC, the
cultures were inspected for CPE. The neutralizing titer, expressed
as the reciprocal of antiserum dilution at which virus growth is
50% inhibited (i.e. where 50% of wells show no CPE), was
calculated by the number of virus negative wells and the serum
dilution.
Determination of PD50 values for immune serum
neutralizing antibodies
The protective dose fifty (PD50), that is, the titer of anti-H5N1
serum neutralizing antibodies required to protect 50% of the
challenged animals from death following challenge with wild-type
virus, was calculated using an in-house software program [42]. To
allow the PD50 to be calculated when this was below the limit of
detection of the MN assay, measured MN titers in each
experiment were compared with corresponding calculated values
based on the original MN titer of the immunizing serum. This
comparison was then used as the basis of linear regression analysis
to extrapolate low dose serum antibody titers from the corre-
sponding calculated titer.
Results
Passive transfer of H5N1 vaccine-induced immune sera
provides dose-dependent protection of CD1 mice
against wild-type H5N1 virus challenge
To evaluate the protective efficacy of immune sera elicited by
a Vero cell culture-derived, whole-virus H5N1 vaccine, CD1
mice were passively immunized and subsequently challenged
with a severe lethal dose of wild-type H5N1 virus. Pooled
immune sera used for passive transfer experiments were
obtained from immunized CD1 mice or guinea pigs, and
human immune sera were collected during a H5N1 phase III
clinical trial. H5N1 neutralizing antibody titers of undiluted
pooled immune sera used for passive transfer experiments were
1:465 (mouse sera), 1:1347 (guinea pig) and 1:147 to 1:830
(human). Groups of ten 6-8-week old, female CD1 mice were
passively immunized with a range of dilutions of immune sera
calculated to achieve the desired circulating serum neutralizing
antibody titers based on a total blood volume of 1.5 ml in
recipient mice. Twenty-four hours following passive transfer,
passively immunized mice were challenged intranasally with 10
4
TCID50, (corresponding to 133 LD50)o fw i l d - t y p eA / V i e t n a m /
1203/2004 H5N1 virus.
Passive immunization provided dose-dependent protection
against lethal H5N1 virus challenge. The data shown in Figure 1
indicate that even very low serum titers of neutralizing H5N1
antibodies were able to substantially delay the onset of death
following lethal H5N1 challenge. More than half of passively
immunized mice survived for at least 14 days following lethal
challenge when circulating serum neutralizing antibody titers were
calculated to be only 1:8, 1:11 and 1:15 for mouse (Figure 1A),
guinea pig (Figure 1B) and human (Figure 1C) whole-virus H5N1
vaccine-induced immune sera, respectively.
Complete protection of 100% of challenged mice for at least 14
days post-virus challenge was provided by mean serum H5N1
neutralizing antibody titers of 1:16 or 1:43 following passive
transfer of mouse (Figure 1A) and guinea pig (Figure 1B) sera,
respectively. Complete protection was also observed in all
experiments where higher titers were used (Table 1). In initial
experiments, complete protection was not provided by passive
transfer of human immune sera at doses expected to achieve
serum antibody titers of up to 1:80. However, the maximum
mean serum titer of H5N1 neutralizing antibodies detectable 22h
after passive transfer of this dose of human immune sera was only
1:29, representing a 64% reduction in titer. This rapid decrease
in neutralizing antibody titer was only observed with human sera;
neutralizing antibody titers measured in animals which were
passively immunized with mouse or guinea pig sera were very
similar to the calculated titers (Table 1). We next investigated
whether full protection of mice might be attained by increasing
the dose of human immune sera used for passive transfer. This
was done by injecting mice with high titer human immune serum
every day for three consecutive days, followed by lethal challenge
with wild-type H5N1 virus 24 h after the third serum transfer. In
four independent experiments, human immune sera calculated to
result in circulating H5N1 antibody titers of between 1:91 and
1:159 were used to immunize a total of 35 mice. Actual serum
neutralizing antibody titers of between 1:22 and 1:104 were
H5N1 Passive Transfer
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serum neutralizing antibody titers achieved by injecting immune
sera on three consecutive days were sufficient to protect 32 out of
the total of 35 challenged mice, demonstrating that passive
transfer of vaccine-induced human immune sera also has the
potential to provide complete protection against H5N1 disease
(Table 1).
Serum neutralizing antibody titers correlate with
protection from H5N1 disease
Due to the lack of wide-spread H5N1 circulation, immune
correlates of vaccine-induced protection have not been established
for H5N1 vaccines. We therefore investigated the relationship
between MN titer and death/survival in the mouse passive transfer
model to determine whether MN titers could be used as an
immune correlate of protection against H5N1 disease. The data in
Figure 2 demonstrate that the titer of H5N1 whole-virus vaccine-
induced serum neutralizing antibodies derived from immunized
mice, guinea pigs and humans all correlated strongly with
protection from severe H5N1 challenge upon passive transfer into
mice.
The correlate of protection currently used for influenza
vaccines is the vaccine-induced hemagglutinin (HA)-specific
antibody titer, as measured by the HI assay. An HI titer of
1:40, corresponding to prevention of disease in 50% of
individuals, is used as a threshold for licensing purposes. To
determine a threshold MN titer which corresponds to 50%
protection against H5N1 disease, PD50 values were calculated for
vaccine-induced mouse, guinea pig and human immune sera in
the passive transfer model (Figure 2 A, B, C, respectively). The
titer of serum neutralizing antibodies derived from all species
correlated with protection from severe H5N1 challenge. The
correlation co-efficient (r
2) for mouse, guinea pig and human
H5N1 immune sera was 0.85, 0.68 and 0.72, respectively.
Moreover, PD50 values were similarly low regardless of serum
source. Mouse, guinea pig or human immune sera were able to
protect half of the challenged animals with neutralizing antibody
titers of 1:5, 1:7 and 1:11, respectively. These data indicate that a
MN titer threshold of 1:20 may be a conservative threshold
appropriate for licensing purposes.
Discussion
These studies were designed to investigate the ability of a Vero
cell-derived, inactivated whole-virus H5N1 vaccine to induce
antibodies which protect against highly pathogenic wild-type virus.
This vaccine was previously demonstrated to protect immunized
mice from challenge with lethal doses of wild-type virus [5,6] and
to be safe and immunogenic in human clinical trials [8,9].
Due to the severity but current low incidence of human H5N1
disease, however, it is neither ethical nor feasible to demonstrate
the clinical efficacy of H5N1 vaccines in placebo-controlled
clinical trials. Here, we used a mouse passive transfer model to
determine the protective efficacy of H5N1 vaccine-induced
immune sera against wild-type H5N1 virus.
The data shown in Figure 1 demonstrate that immune sera from
mice, guinea pigs or humans vaccinated with the whole-virus
H5N1 vaccine provided dose-dependent protection following
challenge with a severe lethal dose of wild-type H5N1 virus.
Complete protection of recipient CD1 mice was provided by
serum neutralizing antibody titers at or above 1:16 and 1:43 for
mouse and guinea pig immune sera, respectively. However, a
single transfer of human immune sera was insufficient to provide
complete protection against virus challenge, probably due to the
observed rapid decrease in human H5N1 neutralizing antibodies
in the CD1 mouse model. However, complete protection could be
achieved by repeated injections of human immune sera to increase
circulating antibody titers.
This is the first report detailing the efficacy of immune sera
elicited by vaccination of humans to protect against lethal H5N1
disease, thus it is not possible to make direct comparisons with
other studies. However, a similar passive protection model in
Figure 1. Prolongation of survival of passively immunized mice
following challenge with wild-type H5N1 virus. Groups of 7 or 10
CD1 mice received immune sera from (A) CD1 mice, (B) guinea pigs or
(C) humans and survival was monitored for 14 days. Shown are the
mean % of surviving animals each day following lethal challenge.
Reciprocal neutralizing antibody titers shown are the means extrapo-
lated from titers measured immediately prior to challenge. N = Naive
serum. All mice receiving mouse immune sera of mean titer $1:16 and
guinea pig immune sera of mean titer $ 1:43 were protected.
doi:10.1371/journal.pone.0023791.g001
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immune sera elicited by an inactivated 2009 pandemic H1N1v
vaccine to protect against challenge with the 1918 Spanish
influenza virus [43]. In this study, mice passively immunized with
100 ml undiluted human immune sera survived for at least 14 days
following challenge with 50 LD50 of 1918 virus, whereas all mice
which received pre-vaccination sera died. We recently used a
SCID mouse passive transfer model to evaluate the efficacy of
antibody-mediated protection elicited by a Vero cell-derived, non-
adjuvanted inactivated whole-virus 2009 pandemic H1N1v
vaccine [29]. Passive transfer of 200 ml undiluted immune serum
from CD1 mice or guinea pigs was found to protect 100% of
SCID mice for at least 30 days, whereas all control animals died
following challenge with a dose of 10
5 TCID50 wild-type H1N1v
virus.
Several groups have used mouse passive transfer models to
demonstrate the protective efficacy of monoclonal antibodies
against lethal H5N1 virus challenge [30–40]. It is difficult to
compare the majority of such studies with the present work since
neutralizing antibody titers are not commonly reported. One
report [38] of passive protection studies using human monoclonal
H5N1 antibodies from IgG
+ memory B cells isolated from
individuals who had recovered from H5N1 infection did however
measure the neutralizing antibody titer of each antibody
preparation against the same A/Vietnam/1203/2004 H5N1
virus used in the present study. From the data presented it can be
calculated (assuming a recipient animal body weight of 20 g, total
blood volume of 1.5 ml and 100% antibody recovery) that serum
neutralizing antibody titers of approximately 1:6 of the most
potent monoclonal antibody protected 100% of Balb/c mice for
at least 14 days following challenge with 10
5 TCID50. A second
monoclonal antibody clone derived from the same individual
required titers of approximately 1:60 to protect 80% of
challenged mice. Thus, taking the different challenge doses into
consideration, lower titers of some highly potent monoclonal
H5N1 antibodies may provide full protection compared to
vaccine-induced sera. This is to be expected since the polyclonal
antibody response generated against vaccination with whole-virus
H5N1 vaccine will consist of a mixture of high and lower potency
neutralizing antibodies. However, whole-virus vaccine-induced
Table 1. Dose-dependent protective efficacy of H5N1 vaccine-induced immune sera in mice.
aExpected titer
bMeasured titer
cExtrapolated titer
dProtection; n/n (%)
Mouse immune sera 40 31 33 20/20 (100)
20 19 16 20/20 (100)
10 ,9.4 8 13/20 (65)
5 ,9.4 4 9/20 (45)
naive ,9.4 n.a. 3/20 (15)
Guinea Pig immune sera 160 170 171 20/20 (100)
80 86 86 20/20 (100)
40 45 43 20/20 (100)
20 20 21 19/20 (95)
10 11 11 11/20 (55)
5 ,9.4 5 5/20 (25)
2.5 ,9.4 3 8/20 (40)
naive ,9.4 n.a. 3/20 (15)
Human immune sera 80 28 29 7/10 (70)
50 17 15 20/30 (67)
38 10 10 3/7 (43)
30 8 8 11/30 (37)
21 ,7.1 6 7/20 (35)
14 ,7.1 4 7/40 (18)
7 ,7.1 2 6/40 (15)
4 ,7.1 1 6/20 (30)
naive ,7.1 n.a. 6/40 (15)
159
e 104 n.a. 9/10 (90)
140
e 48 n.a. 9/10 (90)
113
e 31 n.a. 5/5 (100)
91
e 22 n.a. 9/10 (90)
Shown are reciprocal MN titers:
aexpected titer based on the volume and titer of injected immune sera;
bmeasured circulating titer 2 h prior to challenge;
cextrapolated from titers measured 2 h prior to challengea.
dMice were challenged intranasally with 10
4 TCID50 wild-type H5N1 virus. Animals surviving for $14 days are considered protected.
eImmune serum administered on 3 successive days. n.a., not applicable.
doi:10.1371/journal.pone.0023791.t001
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mutants which may be associated with monoclonal antibodies
[35].
A second goal of our mouse study described here was to
determine the correlation between protective efficacy afforded by
passive transfer of H5N1 vaccine-induced immune sera and
associated H5N1 neutralizing antibody titers. Clinical correlates
of vaccine-induced protection can only be calculated in human
studies; however, since such studies cannot be carried out in the
absence of widespread disease, passive transfer studies such as
those reported here may provide a useful surrogate correlate of
protection indicative of serum titers required to protect against
clinical disease. Licensing guidelines for H5N1 vaccines are
currently based on those established for seasonal influenza
vaccines [2]. A reciprocal HI titer of 40 is generally accepted
as being predictive of a 50% reduction in disease, and this
threshold is used for licensing purposes [44]. However, the HI
assay lacks sensitivity for the evaluation of H5N1 vaccines, and
thus the more sensitive MN assay is commonly used for such
studies [45]. In contrast to the HI assay, which only detects
antibodies capable of preventing binding of influenza virus to
erythrocytes, the MN assay detects all functional antibodies that
interfere with infection. Hence, for H5N1 vaccines, MN titers
may provide a better correlate of protection than HI titers. In the
present study, MN titers were found to correlate strongly with
protection from H5N1 disease (Figure 2). We thus used the MN
assay to calculate the PD50 of serum neutralizing antibody titers
associated with protection from lethal challenge with wild-type
H5N1 virus. The titers of neutralizing serum antibodies required
to protect 50% of animals from challenge with 10
4 TCID50 (133
LD50) wild-type virus, regardless of serum source, was #1:11
(Figure 2). A MN titer of 1:20, as measured using the assay
described here, has also been demonstrated to correlate well with
a SRH seroprotective measurement of 25 mm
2 in sera from
human clinical trials [8].
Taken together, these findings support the confidence that the
Vero-derived whole-virus H5N1 vaccine will be clinically
protective in a pandemic situation. This conclusion is significant
in that non-adjuvanted H5N1 vaccines have generally been
reported to induce lower antibody titers than vaccines which
include novel adjuvants [10,11,46,47]. Also head-to-head
studies with pandemic H1N1v vaccines have demonstrated that
a novel adjuvanted H1N1v egg-derived vaccine induced
significantly higher antibody titers than a non-adjuvanted Vero
cell-derived H1N1v vaccine [48]. The studies reported here
support the conclusion that lower neutralizing antibody titers
are sufficient to confer protection, at least in a sensitive mouse
model of lethal infection. These findings are also supported by
the reports from an efficacy study with a seasonal influenza
vaccine that demonstrated no additional protective efficacy was
provided by HI antibody titers .1:30 [49]. It also indicates that
a MN titer of 1:20 as determined by the assay described here
could be used as a threshold for licensing purposes for H5N1
vaccines.
Acknowledgments
We would like to thank Bianca Hube, Nina Riedel, Nadja Rosenthal,
Cherry Abraham, Nicole Hetzelt, Heherson Michael Albances and Mandy
Reinhardt for their excellent technical support.
Author Contributions
Conception and design of the experiments: MKH NS HS-D OK TRK
PNB. Acquisition of data: NS HS-D. Analysis and interpretation of data:
MKH NS HS-D DP OK TRK HJE PNB. Drafting and critical revision of
article: MKH NS HS-D DP OK TRK HJE PNB. Final approval of the
version to be published: MKH NS HS-D DP OK TRK HJE PNB.
Figure 2. Correlation of survival of passively immunized mice
with neutralizing antibody titer following challenge with wild-
type H5N1 virus. Data points represent the mean % of surviving
animals 14 days following lethal challenge of CD1 mice which had
received immune sera from (A) CD1 mice, (B) guinea pigs or (C)
humans. Reciprocal neutralizing antibody titers shown are extrapolated
from titers measured 2 h prior to challenge. All individual mice
receiving mouse immune sera of titer $1:18 or guinea pig immune
sera of titer $1:37 were protected from disease; these animals are
omitted from the figure to allow better resolution of lower titers.
doi:10.1371/journal.pone.0023791.g002
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